Pan Henan, Wu Zongkai, Gao Yaran, Yao Wentao, Feng Ge, Wang Hebo
Department of Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
Department of Neurology, Hebei General Hospital, Affiliated to Hebei Medical University, No. 348 Heping West Road, Shijiazhuang, Hebei, 050051, China.
BMC Cardiovasc Disord. 2025 Apr 21;25(1):301. doi: 10.1186/s12872-025-04735-3.
BACKGROUND: Atherosclerosis (AS) poses a pressing challenge in contemporary medicine. Glycolysis is a crucial bioenergetic metabolic pathway that provides the primary energy source for endothelial cells. Resveratrol (Res) is a natural compound that has been shown to possess AS. However, the underlying mechanisms of its anti-atherosclerotic effects are not yet fully understood. METHODS: We established a balloon injury model of the common carotid artery in Sprague-Dawley (SD) rats and an ox-LDL endothelial cell injury model for in vivo and in vitro experiments, respectively. RESULTS: Our study showed that 14 days after balloon-induced injury to the carotid intima of SD rats in vitro, the levels of glycolysis-related proteins fructose-2,6-bisphosphatase 3 (PFKFB3), glucose transporter 1 (GLUT1) and hexokinase 2 (HK2) were increased. Meanwhile, Res treatment improved intimal hyperplasia and reduced the levels of expression of these glycolysis-related proteins, and with higher concentrations of Res leading to more pronounced improvements. In vivo, in ox-LDL HUVECs, Res reduced glucose uptake and lactate production, inhibited apoptosis, and decreased the expression of PFKFB3, GLUT1, HK2, and p-AKT. After the addition of a phosphatidylinositol 3-kinase (PI3K) inhibitor, the we established a balloon injury model of the common carotid artery in SD rats and an ox-LDL endothelial cell injury model for in vivo and in vitro experiments, respectively, and expression levels of p-AKT were observed to increase. CONCLUSION: According to these findings, Resveratrol can reduce AS by influencing glycolysis and inhibiting apoptosis through the PI3K-AKT signalling pathway.
BMC Cardiovasc Disord. 2025-4-21
World J Gastroenterol. 2025-3-21
Naunyn Schmiedebergs Arch Pharmacol. 2025-1
BMC Cardiovasc Disord. 2024-5-28
Curr Neuropharmacol. 2025
Pharmaceuticals (Basel). 2024-7-10
Lancet. 2024-6-29
Nat Rev Cardiol. 2024-5
Mol Neurobiol. 2024-8
Int Immunopharmacol. 2023-10
BMC Complement Med Ther. 2023-3-17
Wound Repair Regen. 2023-3
J Cardiovasc Transl Res. 2023-4